Current research on nitazoxanide in the treatment of chronic hepatitis C

Gastroenterology and Hepatology

Volumn 5, Issue 9, 2009, Pages 620-622

  Keeffe, Emmet B ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; INTERFERON; NITAZOXANIDE; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; TELAPREVIR;

ABDOMINAL PAIN; ADD ON THERAPY; ANEMIA; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CHRONIC DISEASE; CHRONIC HEPATITIS; CLINICAL TRIAL; CRYPTOSPORIDIUM PARVUM; DIARRHEA; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; HEPATITIS C; HUMAN; LONG TERM CARE; MEDICAL RESEARCH; MONOTHERAPY; NAUSEA; NOTE; TREATMENT CONTRAINDICATION; VOMITING;

EID: 77954579144     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (8)

1. Korba BE, Montero AB, Farrar K, Gaye K, Mukerjee S et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res. 2008;77:56-63.
2. Korba BE, Elazar M, Lui P, Rossignol JF, Glenn JS. Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob Agents Chemother. 2008;52:4069-4071.
3. Elazar M, Liu M, McKenna S, Liu P, Gehrig EA, et al. The anti-hepatitis C agent nitazoxanide induces phosphorylation of eIF2a via PKR activation. Gastroenterology. In press.
4. Rossignol JF, La Frazia S, Chiappa L, Ciucci A, Santoro MG. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at post-translational level. J Biol Chem. In press.
5. Rossignol J-F, Elfert A, El-Gohary Y, Keeffe EB. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology. 2009;136:856-862.
6. Darling JM, Fried MW. Nitazoxanide: beyond parasites toward a novel agent for hepatitis C. Gastroenterology. 2009;136:760-763.
7. Rossignol JF, Elfert A, Keeffe EB. Evaluation of a 4 week lead-in phase with nitazoxanide (NTZ) prior to peginterferon (PegIFN) plus NTZ for treatment of chronic hepatitis C: final report [abstract]. Hepatology. 2008;48(suppl):1132A-1133A.
8. Keeffe EB, Rossignol JF, Elfert A, Abdelatif S, Cravens L, Phuong TLT. Controlled release tablet improves pharmacokinetics, viral kinetics and tolerability of nitazoxanide for treatment of chronic hepatitis C [abstract]. Hepatol Int. 2009;3:49.